medigraphic.com
ISSN 1561-2988 (Print)

2020, Number 2

<< Back Next >>

Rev Cubana Farm 2020; 53 (2)

Treatment of COVID-19 in Peru and Bolivia, and self-medication risks

Rojas RB, Moscoso S, Ah CS, Limpias TB, Álvarez-Risco A, Yáñez JA

Language: Spanish
References: 80
Page: 1-20
PDF size: 625.03 Kb.


ABSTRACT

Introduction: Various drugs are being used against the symptoms caused by COVID-19, without being approved for these purposes. Many of these drugs have small safety margin and very risky adverse effects on health, a reason why they require prescription and, above all, medical monitoring and follow-up. Unfortunately, there are many cases of selfmedication in Peru and Bolivia that require prompt management. Objective: To carry out a systematic review of the scientific literature that presents evidence about the effectiveness and adverse reactions of the drugs currently used against COVID-19 in Peru and Bolivia. Methods: Qualitative research based on the systematic review of the scientific literature available in PubMed, as well as in the national regulations of Peru and Bolivia related to the etiology, epidemiology, symptoms, as well as treatments approved and discontinued by both countries since the exacerbation of the COVID-19 crisis and the completion of clinical studies to date. Conclusions: The drugs used in Peru and Bolivia for treating COVID-19 have side effects and possible risks to the health of people who unfortunately self-medicate. Greater control of these drugs is required to avoid their free acquisition, and to improve the national and regional strategy to evaluate the possible symptomatic treatments of COVID-19, taking into consideration the high probability of survival of the disease and the risk posed by using these drugs, which, in the future, could cause serious adverse effects on public health in the two countries.


REFERENCES

  1. WHO. Pneumonia of unknown cause-China. Ginebra: World Health Organization; 2020 [acceso 24/05/2020]. Disponible en: https://www.who.int/csr/don/05-january-2020- pneumonia-of-unkown-cause-china/en/

  2. WHO. WHO Timeline - COVID-19. Ginebra: World Health Organization; 2020 [acceso 24/05/2020]. Disponible en: https://www.who.int/news-room/detail/27-04-2020-whotimeline--- covid-19

  3. WHO. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020: World Health Organization; 2020 [acceso 24/05/2020]. Disponible en: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-mediabriefing- on-2019-ncov-on-11-february-2020

  4. WHO. Coronavirus disease (COVID-2019) situation report 126 2020. Ginebra: WHO; 2020 [acceso 25/05/2020]. Disponible en: https://www.who.int/docs/defaultsource/ coronaviruse/situation-reports/20200525-covid-19-sitrep- 126.pdf?sfvrsn=887dbd66_2

  5. MINSA. Sala Situacional COVID-19. Perú: Ministerio de Salud del Perú (MINSA); 2020 [acceso 30/06/2020]. Disponible en: https://covid19.minsa.gob.pe/sala_situacional.asp.

  6. Reporte Epidemiológico Nacional: Bolivia Segura COVID-19; 2020 [acceso 26/05/2020]. Disponible en: https://boliviasegura.gob.bo/

  7. Urrunaga-Pastor D, Benites-Zapata VA, Mezones-Holguín E. Factors associated with self-medication in users of drugstores and pharmacies in Peru: an analysis of the National Survey on User Satisfaction of Health Services, ENSUSALUD 2015. F1000Research. 2019;8:23. DOI: 10.12688/f1000research.17578.2

  8. MINSA. Resolución Ministerial N° 270-2020-MINSA - Prevención, Diagnóstico y Tratamiento de personas afectadas por COVID-19. Perú: MINSA; 2020.

  9. Ministerio de Salud de Bolivia. Guías para el Manejo del COVID-19. Bolivia: Ministerio de Salud; 2020.

  10. Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966;1(7428):76-7. DOI: 10.1016/s0140-6736(66)92364-6

  11. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-80. DOI: 10.1111/tmi.13383

  12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506. DOI: 10.1016/S0140-6736(20)30183-5

  13. Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, a worldwide public health emergency. Rev Clin Esp. 2020:S0014-2565(20)30092-8. DOI: 10.1016/j.rce.2020.03.001

  14. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. DOI: 10.1038/s41586-020-2012-7

  15. GISAID. Phylogeny of SARS-like betacoronaviruses including novel coronavirus SARS-CoV-2; 2020 [acceso 26/05/2020]. Disponible en: https://nextstrain.org/groups/blab/sars-like-cov

  16. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-69. DOI: 10.1038/s41586- 020-2008-3

  17. Lam TT-Y, Shum MH-H, Zhu H-C, Tong Y-G, Ni X-B, Liao Y-S, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature. 2020;583(7815):282-85. DOI: 10.1038/s41586-020-2169-0

  18. Zhang L, Shen FM, Chen F, Lin Z. Origin and evolution of the 2019 novel coronavirus. Clin Infect Dis. 2020. DOI: 10.1093/cid/ciaa112

  19. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565-74. DOI: 10.1016/S0140-6736(20)30251-8

  20. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020:200490. DOI: 10.1148/radiol.2020200490

  21. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. 2020:2020.02.10.20021675. DOI: 10.1101/2020.02.10.20021675

  22. MINSA. Alerta Epidemiológica AE-013-2020: Ministerio de Salud - Centro Nacional de Epidemiología, Prevención y Control de Enfermedades. Perú: MINSA; 2020 [acceso 26/05/2020]. Disponible en: https://www.dge.gob.pe/portal/docs/alertas/2020/AE013.pdf

  23. Infobae. Confirmaron los dos primeros casos de coronavirus en Bolivia: Infobae; 2020 [acceso 24/05/2020]. Disponible en: https://www.infobae.com/america/americalatina/ 2020/03/11/confirmaron-los-dos-primeros-casos-de-coronavirus-en-bolivia/

  24. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. DOI: 10.1038/s41586-020-2012-7

  25. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020;395(10226):809-15. DOI: 10.1016/S0140-6736(20)30360-3

  26. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. DOI: 10.1001/jama.2020.1585

  27. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23. DOI: 10.1016/S0140-6736(20)30154-9

  28. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med 2020;382:1199- 1207. DOI: 10.1056/NEJMoa2001316

  29. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708- 20. DOI: 10.1056/NEJMoa2002032

  30. Bianco A, Buckley AB, Overbey J, Smilen S, Wagner B, Dinglas C, et al. Testing of Patients and Support Persons for Coronavirus Disease 2019 (COVID-19) Infection Before Scheduled Deliveries. Obstetrics and gynecology. 2020;136(2):283-87. DOI: 10.1097/aog.0000000000003985

  31. Noh JY, Yoon JG, Seong H, Choi WS, Sohn JW, Cheong HJ, et al. Asymptomatic infection and atypical manifestations of COVID-19: comparison of viral shedding duration. J Infect. 2020;S0163-4453(20)30310-. DOI: 10.1016/j.jinf.2020.05.035

  32. FDA. Fraudulent Coronavirus Disease 2019 (COVID-19) Products: EE. UU.: Food and Drug Administration; 2020 [acceso 24/05/2020]. Disponible en: https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019- covid-19-products

  33. ClinicalTrials.gov. Clinical Trials for COVID-19 or SARS-CoV-2 2020 [acceso 26/05/2020]. Disponible en: https://clinicaltrials.gov/ct2/results?term=COVID- 19&cond=SARS-CoV-2

  34. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduction and Targeted Therapy. 2020;5(1):57. DOI: 10.1038/s41392-020-0158-2

  35. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020:S0163- 4453(20)30228-0. DOI: 10.1016/j.jinf.2020.04.017

  36. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet; 22 may. 2020. DOI: 10.1016/S0140-6736(20)31180-6 Retracted

  37. PCM. Decreto Supremo Nº 094-2020-PCM - Medidas para la ciudadanía hacia una nueva convivencia y prórroga del Estado de Emergencia. Perú: Presidencia del Consejo de Ministros; 2020.

  38. Ministerio de Salud de Bolivia. “Cuarentena temprana”, la estrategia de Bolivia para contener la pandemia del coronavirus. Bolivia: Ministerio de Salud de Bolivia; 2020 [acceso 24/05/2020]. Disponible en: https://www.minsalud.gob.bo/4149-cuarentena-temprana-laestrategia- de-bolivia-para-contener-la-pandemia-del-coronavirus

  39. MINSA. Normatividad sobre coronavirus (COVID-19). Perú: MINSA; 2020 [acceso 27/05/2020]. Disponible en: https://www.gob.pe/institucion/minsa/colecciones/749- normatividad-sobre-coronavirus-covid-19

  40. Ministerio de Salud de Bolivia. Guías para el Manejo del COVID-19. Bolivia: Ministerio de Salud de Bolivia; 2020.

  41. MINSA. Resolución Ministerial N° 139-2020-MINSA - Documento Técnico: Prevención y Atención de personas afectadas. Perú: MINSA; 2020.

  42. MINSA. Resolución Ministerial N° 193-2020-MINSA - Prevención, Diagnóstico y Tratamiento de personas afectadas por COVID-19 en el Perú. Perú: MINSA; 2020.

  43. MINSA. Resolución Ministerial N° 209-2020-MINSA - Modificación del Documento Técnico: Prevención, Diagnóstico y Tratamiento de personas afectadas. Perú: MINSA; 2020.

  44. MINSA. Resolución Ministerial N° 240-2020-MINSA - Modifican el Documento de Prevención Diagnóstico y Tratamiento. Perú: MINSA; 2020.

  45. SPH. Recomendaciones de la Sociedad Peruana de Hematología al Ministerio de Salud del Perú. Perú: Sociedad Peruana de Hematología; 2020 [acceso 26/05/2020]. Disponible en: http://sph-peru.org/recomendaciones-de-la-sociedad-peruana-de-hematologia-alministerio- de-salud-del-peru/

  46. Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. 2020;4(2). DOI: 10.3399/bjgpopen20X101094

  47. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity reviews. 2020:102554. DOI: 10.1016/j.autrev.2020.102554

  48. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. DOI: 10.1016/j.thromres.2020.04.024

  49. Chawla LS, Moore G, Seneff MG. Incomplete Reversal of Enoxaparin Toxicity by Protamine: Implications of Renal Insufficiency, Obesity, and Low Molecular Weight Heparin Sulfate Content. Obesity Surgery. 2004;14(5):695-8. DOI: 10.1381/096089204323093516

  50. Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai MC. QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. Heart rhythm. 2020. DOI: 10.1016/j.hrthm.2020.05.008

  51. Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? Journal of the American Academy of Dermatology. 2020;82(6):e221. DOI: 10.1016/j.jaad.2020.04.017

  52. Choudhary R, Sharma AK, Choudhary R. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020;35:100684. DOI: 10.1016/j.nmni.2020.100684

  53. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020;178:104787. DOI: 10.1016/j.antiviral.2020.104787

  54. Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral research. 2020;178:104805. DOI: 10.1016/j.antiviral.2020.104805

  55. ClinicalTrials.gov. Clinical Trials for COVID-19 and Ivermectin. EE. UU.: ClinicalTrials.gov; 2020 [acceso 25/05/2020]. Disponible en: https://clinicaltrials.gov/ct2/results?term=ivermectin&cond=covid+19

  56. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-6. DOI: 10.1136/thorax.2003.012658

  57. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England journal of medicine. 302020;382(19):1787-99. DOI: 10.1056/NEJMoa2001282

  58. Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus Apher Sci. 2020:102790-. DOI: 10.1016/j.transci.2020.102790

  59. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity reviews. 2020:102554-. DOI: 10.1016/j.autrev.2020.102554

  60. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020;92:1475-1483. DOI: 10.1002/jmv.25961

  61. EFE. La presidenta de Bolivia cambia al ministro de Salud en plena emergencia: Agencia EFE; 2020 [acceso 24/05/2020]. Disponible en: https://www.efe.com/efe/america/politica/la-presidenta-de-bolivia-cambia-al-ministrosalud- en-plena-emergencia/20000035-4216947

  62. Infobae. Detuvieron al ministro de Salud de Bolivia por la compra de respiradores al triple del precio de mercado. Argentina: Infobae; 2020 [acceso 27/05/2020]. Disponible en: https://www.infobae.com/america/america-latina/2020/05/20/detuvieron-al-ministro-desalud- de-bolivia-por-la-compra-de-respiradores-al-triple-del-precio-de-mercado/.

  63. Alvarez-Risco A, Mejia CR, Delgado-Zegarra J, Del-Aguila-Arcentales S, Arce- Esquivel AA, Valladares-Garrido MJ, et al. The Peru Approach against the COVID-19 Infodemic: Insights and Strategies. The American Journal of Tropical Medicine and Hygiene. 2020;103(2):583-6. DOI: 10.4269/ajtmh.20-0536.

  64. Yáñez JA, Alvarez-Risco A, Delgado-Zegarra J. Rapid Response: Does Peru really have that high number of COVID-19 confirmed cases? The deception of combining RT-PCR and rapid test results: BMJ. 2020 [acceso 01/07/2020];369:m2518. Disponible en: https://www.bmj.com/content/369/bmj.m2518/rr-4

  65. Yanez JA, Chung SA, Inga-Berrospi F, Mejia CR. Demographic and Geographic COVID-19 Death Risk Factors in Peru. A Nationwide Analysis. 10 jul. 2020. DOI: 10.2139/ssrn.3648543

  66. Yáñez JA, Alvarez-Risco A, Delgado-Zegarra J. Rapid Response: Clearing the path for COVID-19 in Peru? The decision of supervised walks for children and adolescents: BMJ. 2020 [acceso 03/06/2020];369:m2418. Disponible en: https://www.bmj.com/content/369/bmj.m1918/rr-9

  67. Yáñez JA, Alvarez-Risco A, Delgado-Zegarra J. Covid-19 in Peru: from supervised walks for children to the first case of Kawasaki-like syndrome. BMJ (Clinical research ed.) 2020;369:m2418. DOI: 10.1136/bmj.m2418

  68. Yáñez JA, Afshar Jahanshahi A, Alvarez-Risco A, Li J, Zhang SX. The anxiety, distress and turnover intention of healthcare workers in Peru by their distance to the epicenter during the COVID-19 crisis. The American Journal of Tropical Medicine and Hygiene. 2020; In Press.

  69. Chen X, Zhang SX, Jahanshahi AA, Alvarez-Risco A, Dai H, Li J, et al. Belief in Conspiracy Theory about COVID-19 Predicts Mental Health and Well-being: A Study of Healthcare Staff in Ecuador. JMIR Public Health Surveillance. 2020;6(3):e20737 DOI: 10.2196/20737

  70. Zhang SX, Chen J, Jahanshahi AA, Alvarez-Risco A, Dai H, Li J, et al. Succumbing to the COVID-19 Pandemic – Healthcare Workers not Satisfied and Intend to Leave Their Jobs. JMIR Preprints. 2020. DOI: 10.2196/preprints.21870

  71. Automedicación para COVID-19 genera nuevos retos en la resistencia antimicrobiana: El Hospital; 2020 [acceso 24/05/2020]. Disponible en: http://www.elhospital.com/temas/Automedicacion-para-COVID-19-genera-nuevos-retosen- la-resistencia-antimicrobiana+133642

  72. Wong A. COVID-19 and toxicity from potential treatments: Panacea or poison. Emergency medicine Australasia : EMA. 2020;32(4). DOI: 10.1111/1742-6723.13537.

  73. WHO. La resistencia a los antimicrobianos. Ginebra: WHO; 2020 [acceso 24/05/2020]. Disponible en: https://www.who.int/antimicrobial-resistance/es/

  74. Byrne AL, Fox GJ, Marais BJ. Better than a pound of cure: preventing the development of multidrug-resistant tuberculosis. Future microbiology. 2018;13:577-88. DOI: 10.2217/fmb-2017-0236

  75. Zaidel EJ, Wyss Quintana FS, Sosa Liprandi Á, Mendoza I, Márquez MF, Nuñez E, et al. [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic]. Medicina. 2020;80(3):271-4.

  76. Theodore Coroneo M. The eye as the discrete but defensible portal of coronavirus infection. The ocular surface. De próxima aparición 2020. DOI: 10.1016/j.jtos.2020.05.011

  77. FDA. Carta de la FDA a las partes interesadas: No use Ivermectina destinada a animales como tratamiento para el COVID-19 en humanos. EE. UU.: FDA; 2020 [acceso 24/05/2020]. Disponible en: https://www.fda.gov/animal-veterinary/product-safety information/carta-de-la-fda-las-partes-interesadas-no-use-ivermectina-destinada-animalescomo- tratamiento-para.

  78. Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, et al. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID- 19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies. 2020;75(4):371-379. DOI: 10.1016/j.therap.2020.05.002

  79. WHO warns against self-medicating for COVID-19 with aspirin, lemon juice and honey 'remedy': AFP Fact Check; 2020 [acceso 24/05/2020]. Disponible en: https://factcheck.afp.com/who-warns-against-self-medicating-covid-19-aspirin-lemonjuice- and-honey-remedy.

  80. WHO. Preguntas y respuestas sobre la enfermedad por coronavirus (COVID-19). Ginebra: World Health Organization; 2020 [acceso 24/05/2020]. Disponible en: https://factcheck.afp.com/who-warns-against-self-medicating-covid-19-aspirin-lemonjuice- and-honey-remedy.




2020     |     www.medigraphic.com